MONOPRIL
LOE ApproachingNDAORALTABLET
Approved
May 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOPRIL is an oral small-molecule tablet approved by the FDA in 1991 as an NDA product. The generic name and mechanism of action are not currently available in this dataset. This product is marketed by Bristol Myers Squibb.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating potential team consolidation and focus on defending market position against generics.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MONOPRIL offers experience managing a mature product through LOE transition, which builds valuable skills in competitive defense, generic conversion strategies, and commercial efficiency. However, limited linked job openings (0) indicate a smaller team footprint, suggesting this is better suited as a transition or defensive portfolio role rather than a growth opportunity.
Brand Manager
Worked on MONOPRIL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.